The purpose of this clinical trial is to demonstrate that cardiac output (CO) as determined with the Clinical Platform (Model:EV1000A, Software Version:1.9) in a noninvasive manner is comparable to CO as determined by Pulmonary Artery Catheter (PAC) thermodilution (TD). The results of this study may be used for registration and regulatory submissions.
Study Type
OBSERVATIONAL
Enrollment
125
EV1000NI Clinical Platform: Noninvasive Hemodynamic Monitoring utilizing ClearSight System
Fuwai Cardiovascular Disease Hospital, Chinese Academy of Medical Sciences, Beijing
Xicheng, Beijing Municipality, China
Wuhan Asia Heart Hospital
Wuhan, Hubei, China
Tianjin Chest Hospital
Xiaobailou, Tianjin Municipality, China
Cardiac Output using the Non-invasive ClearSight System
Cardiac Output using the Non-invasive ClearSight System
Time frame: Expected to last no more than 6 hours
The percentage error (PE) between the ClearSight System CO and TD
The percentage error (PE) between the ClearSight System CO and TD
Time frame: Expected to last no more than 6 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.